351
Participants
Start Date
April 24, 2017
Primary Completion Date
November 23, 2018
Study Completion Date
March 14, 2023
Trastuzumab Emtansine
Trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) was administered intravenously on Day 1 of each 21-day cycle.
Lapatinib
Lapatinib 1250 mg was administered orally once per day of each 21-day cycle.
Capecitabine
Capecitabine 1000 milligrams per square meter (mg/m\^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
Beijing Hospital, Beijing
The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA), Beijing
Beijing Cancer Hospital, Beijing
Liaoning cancer Hospital & Institute, Shenyang
the First Hospital of Jilin University, Changchun
Jilin Cancer Hospital, Changchun
Harbin Medical University Cancer Hospital, Harbin
Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital), Shanghai
Fudan University Shanghai Cancer Center, Shanghai
Jiangsu Province Hospital, Nanjing
Jiangsu Cancer Hospital, Nanjing
Changzhou First People's Hospital, Changzhou
Tianjin Cancer Hospital, Tianjin
The Second Affiliated Hospital of Zhejiang University College, Hangzhou
Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department, Hangzhou
Fujian Medical University Union Hospital, Fuzhou
West China Hospital, Sichuan University, Chengdu
First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an
Hoffmann-La Roche
INDUSTRY